Skip to main content
. 2017 Aug 21;2(4):432–440. doi: 10.1002/epi4.12074

Table 1.

Patient demographics

Control, n = 31 Nonepileptic, n = 28 Epilepsy, n = 31 p
Age, mo 79 ± 12 49 ± 9 71 ± 11 NS
Gender, M/F 20/11 21/7 18/13 NS
PICU LOS, days 3 [0.4–28] 2 [0.5–18] 1 [0.5–24] NS
Seizure duration, min NA 30 ± 9a 31 ± 11b NS
Generalized tonic–clonic seizures 14 (50%) 18 (58%) NS
Febrile status epilepticus NA 5 (18%) 0 (0%) <0.05
Number of acute AEDs NA 2 [1–3] 2 [0–3] NS
Fosphenytoin use NA 17 (61%) 16 (52%) NS
Interval between seizure cessation and ECG, h NA 5 [1.5–15] 3 [1–4.8] NS
ECG indication
Seizure etiology evaluation 0 11 (39%) 5 (16%) NS
Tachycardia 6 (19%) 1 (4%) 2 (7%)
Bradycardia 2 (6%) 1 (4%) 1 (3%)
Atrial tachycardia 2 (6%) 0 0
Arrhythmia 4 (13%) 4 (14%) 6 (19%)
Evaluate ST segment 0 6 (21%) 8 (26%)
Evaluate QT interval 1 (3%) 2 (7%) 4 (13%)
Evaluate heart disease 9 (29%) 0 0
Chest pain 3 (10%) 0 0
Otherc 4 (13%) 3 (11%) 5 (16%)

Values are expressed as mean ± standard error of the mean, median [min–max], or n (%).

AED, antiepileptic drug; ECG, electrocardiogram; F, female; LOS, length of stay; M, male; NS, not significant; PICU, Pediatric Intensive Care Unit.

a

n = 22.

b

n = 25.

c

Other indications include syncope, murmur, hypertension, and hyperkalemia.